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Finding FEV6 to be less than FVC in cases over 40
years, is not a major concern for our study as stated
in Dr. Crapo’s letter. Our real concern was to find
FEV6 to be less than FVC in cases with obstruction,
and to see this leading to underestimation espe-
cially in cases with mild obstruction. The difference
between FVC and FEV6 was 180mL in cases with
obstruction in our study; the same difference was
found to be only 44mL in cases without obstruc-
tion.1 The decreasing FEV6 values with increasing
age may simply be due to increasing levels of
obstruction in the aging population. Using the lower
limits as proposed by Dr. Crapo may in fact also be
used for FVC due to the increasing obstruction by
age. This subject has been brought about and
discussed in a ‘The ATS-ERS Consensus on Clinical
Pulmonary Function Testing’ symposium in the
recent 2005 ATS congress, too. However, currently,
the most important reference in the field of
obstruction, namely GOLD, suggests a fixed ob-
struction parameter (FEV1/FVCo70%).2 If a lower
limit is suggested to be used for FEV6, it should beee front matter & 2005 Elsevier Ltd. All rights reserv
med.2005.07.002applied to FVC, too. We think that no remarkable
difference would be seen in the results while
evaluating the FEV1/FEV6 in the end. Also the
relative simplicity of using FEV6 in place of FVC
would be sacrificed if lower limits for FEV6 are
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